{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:05:17Z","timestamp":1790773517013,"version":"4.1.0"},"reference-count":311,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejphar.2023.176230","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T19:59:47Z","timestamp":1701374387000},"page":"176230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Targets, trials and tribulations in Alzheimer therapeutics"],"prefix":"10.1016","volume":"962","author":[{"given":"Ruchita","family":"Gharat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gargi","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Khambete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3637-8964","authenticated-orcid":false,"given":"Arati","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.176230_bib1","author":"AC Immune"},{"key":"10.1016\/j.ejphar.2023.176230_bib2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/brain\/awz100","article-title":"Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody","volume":"142","author":"Albert","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2023.176230_bib3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1096\/fj.07-8627rev","article-title":"Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators","volume":"22","author":"Amit","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.ejphar.2023.176230_bib4","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/S0140-6736(17)32399-1","article-title":"Why do so many clinical trials of therapies for Alzheimer's disease fail?","volume":"390","author":"Anderson","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.176230_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092313","article-title":"Natural compounds for alzheimer's disease therapy: a systematic review of preclinical and clinical studies","volume":"20","author":"Andrade","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.176230_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1567205012666150302154121","article-title":"Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate alzheimer\u2019 s disease: results from two phase 2 studies","volume":"12","author":"Arai","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2023.176230_bib7","first-page":"106","article-title":"Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis","volume":"87","author":"Arrighi","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176230_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.mcna.2018.10.009","article-title":"The alzheimer's disease clinical spectrum: diagnosis and management","volume":"103","author":"Atri","year":"2019","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.ejphar.2023.176230_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00042192-200512010-00005","article-title":"Early postmenopausal hormone therapy may prevent cognitive impairment later in life","volume":"12","author":"Bagger","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.ejphar.2023.176230_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cbpa.2008.02.019","article-title":"Metals in Alzheimer's and Parkinson's diseases","volume":"12","author":"Barnham","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejphar.2023.176230_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004836-199801000-00015","article-title":"Tacrine. A cause of fatal hepatotoxicity?","volume":"26","author":"Blackard","year":"1998","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2023.176230_bib14","article-title":"P2\u2010003: clinical trial design of Cread: a randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010Group phase 3 study to evaluate Crenezumab","volume":"12","author":"Blaettler","year":"2016","journal-title":"Wiley Online Libr"},{"key":"10.1016\/j.ejphar.2023.176230_bib15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","article-title":"Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease","volume":"69","author":"Blennow","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-010-0705-y","article-title":"Reduction of aggregated Tau in neuronal processes but not in the cell bodies after A\u03b242 immunisation in Alzheimer's disease","volume":"120","author":"Boche","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2023.176230_bib17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide for Progressive Supranuclear Palsy: a multicenter, randomized, double-blind, placebo controlled trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/hmg\/5.10.1589","article-title":"cDNA cloning and chromosome mapping of the human Fe65 gene: interaction of the conserved cytoplasmic domains of the human beta-amyloid precursor protein and its homologues with the mouse Fe65 protein","volume":"5","author":"Bressler","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejphar.2023.176230_bib21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","article-title":"Human secreted tau increases amyloid-beta production","volume":"36","author":"Bright","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2023.176230_bib22","article-title":"The estrogen replacement therapy of the Women's Health Initiative promotes the cellular mechanisms of memory and neuronal survival in neurons vulnerable to Alzheimer's disease","volume":"34","author":"Brinton","year":"2000","journal-title":"Maturitas"},{"key":"10.1016\/j.ejphar.2023.176230_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2009.08.031","article-title":"Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors","author":"Brunden","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib24","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.3059-10.2010","article-title":"Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy","volume":"30","author":"Brunden","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib25","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1523\/JNEUROSCI.3059-10.2010","article-title":"Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy","volume":"30","author":"Brunden","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.wad.0000201847.29836.a5","article-title":"Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date","volume":"20","author":"Bullock","year":"2006","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.ejphar.2023.176230_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e318279bcfa","article-title":"Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate alzheimer disease","volume":"36","author":"Burstein","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2023.176230_bib28","first-page":"1","article-title":"Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation Endproducts, for the potential slowing of loss of cognition in mild alzheimer's disease","volume":"5","author":"Burstein","year":"2018","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3233\/JAD-132690","article-title":"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"41","author":"Cc","year":"2014","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib30","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-160701","article-title":"AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with alzheimer's disease","volume":"55","author":"Cebers","year":"2017","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib31","first-page":"201","article-title":"Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide","volume":"119","author":"Cehlar","year":"2018","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.ejphar.2023.176230_bib32","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1046\/j.1471-4159.2000.0721327.x","article-title":"The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3","volume":"72","author":"Chen","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2023.176230_bib33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: structure, biology and structure-based therapeutic development","volume":"389 38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2023.176230_bib34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","article-title":"Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2023.176230_bib35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2967\/jnumed.118.209130","article-title":"Impact of Reference and target region selection on amyloid PET SUV Ratios in the phase 1b PRIME study of aducanumab","volume":"60","author":"Chiao","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the \u03b3-secretase inhibitor Avagacestat in a phase 2 study of mild to moderate alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0891988719882102","article-title":"The neuropsychiatric Inventory: development and Applications","volume":"33","author":"Cummings","year":"2020","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib38","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1176\/appi.ajp.161.3.532","article-title":"Reduction of behavioral disturbances and Caregiver distress by galantamine in patients with alzheimer's disease","volume":"161","author":"Cummings","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176230_bib39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejphar.2023.176230_bib40","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphan-quinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial","volume":"314","author":"Cummings","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2023.176230_bib41","article-title":"Alzheimer's disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2023.176230_bib42","article-title":"Alzheimer's disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2023.176230_bib43","article-title":"Alzheimer's disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2023.176230_bib44","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1212\/WNL.59.4.563","article-title":"Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months","volume":"59","author":"Darreh-Shori","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.176230_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3940(01)01586-5","article-title":"Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease","volume":"300","author":"Davidsson","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2023.176230_bib46","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199210293271801","article-title":"A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group","volume":"327","author":"Davis","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib47","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for alzheimer's disease: Prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-444-54299-1.00001-7","article-title":"Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future","volume":"197","author":"de la Torre","year":"2012","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejphar.2023.176230_bib49","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1474-4422(16)30034-5","article-title":"Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"15","author":"de la Torre","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib50","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm890","article-title":"RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain","volume":"9","author":"Deane","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib51","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1523\/JNEUROSCI.1487-05.2005","article-title":"Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase","volume":"25","author":"Derkinderen","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib52","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3233\/JAD-121501","article-title":"Blood Transcriptomic biomarkers of alzheimer's disease patients treated with EHT 0202","volume":"34","author":"D\u00e9sir\u00e9","year":"2013","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib54","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40262-012-0005-x","article-title":"A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of Avagacestat (BMS-708163) in healthy young and elderly subjects","volume":"5110 51","author":"Dockens","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2023.176230_bib55","first-page":"595","article-title":"The role of tau kinases in Alzheimer's disease","volume":"13","author":"Dolan","year":"2010","journal-title":"Curr. Opin. Drug Discov. Dev"},{"key":"10.1016\/j.ejphar.2023.176230_bib56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of Solanezumab for mild-to-moderate alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-015-0121-6","article-title":"Peripheral and central effects of \u03b3-secretase inhibition by semagacestat in Alzheimer's disease","volume":"7","author":"Doody","year":"2015","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib59","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.2174\/0929867323666161213101126","article-title":"Alzheimer's disease: a review from the pathophysiology to diagnosis, new Perspectives for pharmacological treatment","volume":"25","author":"dos Santos Picanco","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.176230_bib60","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","article-title":"Increased CSF APPs-a levels in patients with Alzheimer disease treated with acitretin","volume":"83","author":"Endres","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.176230_bib61","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","article-title":"Increased CSF APPs-\u03b1 levels in patients with Alzheimer disease treated with acitretin","volume":"83","author":"Endres","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.176230_bib62","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000008243","article-title":"A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease","volume":"44","author":"Farlow","year":"2000","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active A\u03b2 immunotherapy with CAD106 in mild Alzheimer's disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active A\u03b2 immunotherapy with CAD106 in mild Alzheimer's disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib65","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-180759","article-title":"A randomized, double-blind, placebo-controlled, phase II study Assessing safety, tolerability, and efficacy of Bryostatin in the treatment of moderately severe to severe alzheimer's disease","volume":"67","author":"Farlow","year":"2019","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib66","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00109-007-0156-7","article-title":"Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology","volume":"85","author":"Fenili","year":"2007","journal-title":"J. Mol. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176230_bib67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer\u2019s disease: targeting the cholinergic system","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2023.176230_bib68","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2023.176230_bib69","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/1097-4547(20001101)62:3<463::AID-JNR16>3.0.CO;2-7","article-title":"Phosphorylation of human tau protein by microtubule-associated kinases: GSK3\u03b2 and cdk5 are key participants","volume":"62","author":"Flaherty","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2023.176230_bib70","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.176230_bib71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nrleng.2015.03.019","article-title":"Review of the advances in treatment for Alzheimer disease: strategies for combating \u03b2-amyloid protein","volume":"33","author":"Folch","year":"2018","journal-title":"Neurol. (English Ed."},{"key":"10.1016\/j.ejphar.2023.176230_bib72","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1007\/s00018-007-7045-7","article-title":"Glycogen synthase kinase 3: a key regulator of cellular fate","volume":"64","author":"Forde","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2023.176230_bib73","series-title":"Healthy Subjects and in Subjects with Mild Cognitive Impairment or Early Alzheimer's Disease","article-title":"Safety, tolerability, pharmacokinetics of EVP-0962 and effects of EVP-0962 on cerebral spinal fluid amyloid Concentrations","year":"2014"},{"key":"10.1016\/j.ejphar.2023.176230_bib74","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/WAD.0b013e31815d1048","article-title":"Safety, tolerability, pharmacokinetics, and A\u03b2 levels after short-term administration of R-flurbiprofen in healthy elderly individuals","volume":"21","author":"Galasko","year":"2007","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.ejphar.2023.176230_bib75","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archpsyc.55.9.809","article-title":"The relationships between age, Sex, and the incidence of dementia and alzheimer disease: a meta-analysis","volume":"55","author":"Gao","year":"1998","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.ejphar.2023.176230_bib76","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejphar.2023.176230_bib77","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fnagi.2014.00342","article-title":"Complex regulation of \u03b3-secretase: from obligatory to modulatory subunits","volume":"6","author":"Gertsik","year":"2015","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib78","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1006\/hbeh.1998.1451","article-title":"Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline","volume":"34","author":"Gibbs","year":"1998","journal-title":"Horm. Behav."},{"key":"10.1016\/j.ejphar.2023.176230_bib79","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.176230_bib80","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1073\/pnas.85.11.4051","article-title":"Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau","volume":"85","author":"Goedert","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176230_bib81","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2023.176230_bib82","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00702-004-0221-0","article-title":"Post-translational modifications of tau protein in Alzheimer's disease","volume":"112","author":"Gong","year":"2005","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.ejphar.2023.176230_bib83","doi-asserted-by":"crossref","DOI":"10.1186\/alzrt272","article-title":"Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics","volume":"6","author":"Goure","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1999.tb07884.x","article-title":"A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein","volume":"897","author":"Gozes","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2023.176230_bib85","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2023.176230_bib86","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of Brexpiprazole for the treatment of agitation in alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176230_bib87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.neuint.2012.12.005","article-title":"Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain","volume":"62","author":"Guo","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2023.176230_bib88","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176230_bib89","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer's disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2023.176230_bib90","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib91","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s13346-011-0050-2","article-title":"Intranasal delivery of deferoxamine reduces spatial memory loss in APP\/PS1 mice","volume":"2","author":"Hanson","year":"2012","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejphar.2023.176230_bib92","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","article-title":"The amyloid hypothesis for Alzheimer's disease: a critical reappraisal","volume":"110","author":"Hardy","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2023.176230_bib93","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1460-9568.2009.07052.x","article-title":"Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease","volume":"31","author":"Hawkes","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00324","article-title":"Perturbations of Ubiquitin-Proteasome-mediated Proteolysis in aging and alzheimer's disease","volume":"11","author":"Hegde","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib95","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M508460200","article-title":"Amyloid \u03b2-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor","volume":"280","author":"Hemming","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2023.176230_bib96","first-page":"91","article-title":"Methodological aspects of the phase II study AFF006 evaluating amyloid-beta -targeting vaccine AFFITOPE\u00ae AD02 in early alzheimer's disease \u2013 prospective Use of novel Composite scales","volume":"2","author":"Hendrix","year":"2015","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib97","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib98","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMc1813435","article-title":"Preliminary results of a trial of atabecestat in preclinical alzheimer's disease","volume":"380","author":"Henley","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib99","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1021\/jm060434q","article-title":"N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src\/Abl kinase inhibitor","volume":"49","author":"Hennequin","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.176230_bib100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial","volume":"16","author":"Herring","year":"2020","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.ejphar.2023.176230_bib101","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized placebo-controlled trial of Nabilone for agitation in alzheimer's disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176230_bib102","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0306-4522(00)00410-3","article-title":"The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis","volume":"101","author":"Hogervorst","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2023.176230_bib103","series-title":"Articles Long-Term Eff Ects of A\u03b2 42 Immunisation in Alzheimer's Disease: Follow-Up of a Randomised, Placebo-Controlled Phase I Trial","author":"Holmes","year":"2008"},{"key":"10.1016\/j.ejphar.2023.176230_bib104","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for mild dementia due to alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for mild dementia due to alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib106","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jcph.393","article-title":"Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease","volume":"55","author":"Hu","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176230_bib107","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease","volume":"27","author":"Huang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejphar.2023.176230_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007000","article-title":"Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain","volume":"5","author":"Hudry","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib109","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","article-title":"Investigational BACE inhibitors for the treatment of Alzheimer's disease","volume":"28","author":"Imbimbo","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2023.176230_bib110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/WAD.0b013e3182622ace","article-title":"Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects","volume":"27","author":"Imbimbo","year":"2013","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.ejphar.2023.176230_bib111","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF02802025","article-title":"Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease","volume":"17","author":"Inestrosa","year":"1998","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2023.176230_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2018.07.212","article-title":"P4\u2010388: trailblazer\u2010alz (NCT03367403): a phase 2 disease\u2010modification combination therapy trial targeting multiple mechanisms of action along the amyloid pathway","volume":"14","author":"Irizarry","year":"2018","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2023.176230_bib113","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0193-y","article-title":"Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies","volume":"8","author":"Ivanoiu","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib114","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0193-y","article-title":"Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies","volume":"8","author":"Ivanoiu","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib115","doi-asserted-by":"crossref","first-page":"13065","DOI":"10.1016\/S0021-9258(17)36796-0","article-title":"Estrogen regulates metabolism of Alzheimer amyloid \u03b2 precursor protein","volume":"269","author":"Jaffe","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2023.176230_bib116","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF02252926","article-title":"Brain iron and ferritin in Parkinson's and Alzheimer's diseases","volume":"2","author":"Jellinger","year":"1990","journal-title":"J. Neural Transm. - Park. Dis. Dement. Sect."},{"key":"10.1016\/j.ejphar.2023.176230_bib117","series-title":"Past , Present and Future of Therapeutic Strategies against Amyloid- \u03b2 Peptides in Alzheimer \u2019 S Disease : a Systematic Review 72","author":"Jeremic","year":"2021"},{"key":"10.1016\/j.ejphar.2023.176230_bib118","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00004714-199912000-00005","article-title":"Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans","volume":"19","author":"Kennedy","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2023.176230_bib119","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer's disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate alzheimer's disease patients","volume":"57","author":"Ketter","year":"2017","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib121","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1046\/j.1471-4159.2002.01016.x","article-title":"Direct visualization of the gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus","volume":"82","author":"Kinoshita","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2023.176230_bib122","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib123","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib124","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.10372","article-title":"Effect of Rotigotine vs placebo on cognitive functions among patients with mild to moderate alzheimer disease: a randomized clinical trial","volume":"3","author":"Koch","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejphar.2023.176230_bib125","doi-asserted-by":"crossref","DOI":"10.1186\/alzrt277","article-title":"Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib126","doi-asserted-by":"crossref","first-page":"24374","DOI":"10.1016\/S0021-9258(20)80536-5","article-title":"Microtubule-associated protein tau. Abnormal phosphorylation of a non- paired helical filament pool in Alzheimer disease","volume":"268","author":"Kopke","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2023.176230_bib127","doi-asserted-by":"crossref","DOI":"10.17116\/jnevro20151156103-114","article-title":"Molecular aspects of the pathogenesis and current approaches to pharmacological correction of Alzheimer's disease","author":"Kukharsky","year":"2015","journal-title":"Zhurnal Nevrol. i Psihiatr. Im. S.S. Korsakova."},{"key":"10.1016\/j.ejphar.2023.176230_bib128","doi-asserted-by":"crossref","DOI":"10.15406\/japlr.2018.07.00230","article-title":"Pathophysiology and management of alzheimer's disease: an overview","volume":"7","author":"Kumar Thakur","year":"2018","journal-title":"J. Anal. Pharm. Res."},{"key":"10.1016\/j.ejphar.2023.176230_bib129","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2019.1665453","article-title":"Rationale for the development of an Alzheimer's disease vaccine","volume":"16","author":"Kwan","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ejphar.2023.176230_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b2 40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase i trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib131","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b2 40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib132","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2147\/NDT.S203103","article-title":"What are the links between hypoxia and Alzheimer's disease?","volume":"15","author":"Lall","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ejphar.2023.176230_bib133","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.trci.2017.05.003","article-title":"Ponezumab in mild-to-moderate Alzheimer's disease: randomized phase II PET-PIB study","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2023.176230_bib134","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0969-9961(03)00079-2","article-title":"Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype","volume":"13","author":"Lanz","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clineuro.2016.04.021","article-title":"Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy","volume":"146","author":"Leclair-Visonneau","year":"2016","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ejphar.2023.176230_bib136","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ana.20592","article-title":"A\u03b242 immunization in Alzheimer's disease generates A\u03b2 N-terminal antibodies","volume":"58","author":"Lee","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib137","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-mediated targeting of tau in vivo does not Require effector function and microglial engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2023.176230_bib138","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jnc.15007","article-title":"A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A\u03b2 oligomers from Alzheimer's brain","volume":"154","author":"Li","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2023.176230_bib139","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-7091-6641-3_6","article-title":"Cognitive disturbances in progressive supranuclear palsy","volume":"42","author":"Litvan","year":"1994","journal-title":"J. Neural. Transm. Suppl."},{"key":"10.1016\/j.ejphar.2023.176230_bib140","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1073\/pnas.0400348101","article-title":"O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease","volume":"101","author":"Liu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176230_bib141","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/brain\/awp099","article-title":"Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease","volume":"132","author":"Liu","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2023.176230_bib142","article-title":"Amyloid-\u03b2 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.176230_bib143","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","article-title":"Amyloid-\u03b2 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.176230_bib144","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-142508","article-title":"Cognitive impairment Precedes and Predicts functional impairment in mild alzheimer's disease","volume":"47","author":"Liu-Seifert","year":"2015","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib145","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib146","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib147","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1212\/WNL.48.6.1521","article-title":"EEG spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer's disease","volume":"48","author":"Lopez","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.176230_bib148","first-page":"242","article-title":"The alzheimer's prevention initiative generation program: Evaluating CNP520 efficacy in the prevention of alzheimer's disease","volume":"4","author":"Lopez","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib149","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.trci.2019.02.005","article-title":"The Alzheimer's Prevention Initiative Generation Program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease","volume":"5","author":"Lopez","year":"2019","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"issue":"3","key":"10.1016\/j.ejphar.2023.176230_bib150","first-page":"41","article-title":"D-pinitol, a highly valuable product from carob pods: health-promoting effects and metabolic pathways of this natural super-food ingredient and its derivatives","volume":"141","author":"L\u00f3pez-S\u00e1nchez","year":"2018","journal-title":"AIMS Agric. Food"},{"key":"10.1016\/j.ejphar.2023.176230_bib151","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer's disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib152","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/B978-0-12-394816-8.00006-4","article-title":"scyllo-Inositol, preclinical, and clinical data for Alzheimer's disease","volume":"64","author":"Ma","year":"2012","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176230_bib153","doi-asserted-by":"crossref","first-page":"P668","DOI":"10.1016\/j.jalz.2013.05.1378","article-title":"P3\u2013303: a randomized, double\u2010blind, placebo\u2010controlled, multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of a microtubule stabilizer (BMS\u2010241027) in healthy females","volume":"9","author":"Malamut","year":"2013","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2023.176230_bib154","series-title":"Development of AFFITOPE Alzheimer Vaccines: Results of Phase I Studies with AD01 and AD02","author":"Mandler","year":"2011"},{"key":"10.1016\/j.ejphar.2023.176230_bib155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biology9120425","article-title":"Vaccination against \u03b2-amyloid as a strategy for the prevention of alzheimer's disease","volume":"9","author":"Mantile","year":"2020","journal-title":"Biology"},{"key":"10.1016\/j.ejphar.2023.176230_bib156","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/jm011020u","article-title":"First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease","volume":"45","author":"Martinez","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.176230_bib157","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.107.130526","article-title":"A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease","volume":"325","author":"Matsuoka","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib158","article-title":"The effects of Rasagiline on glucose metabolism and cognition and their relationship to tau burden in a double-blind, placebo-controlled phase Ii clinical trial of participants with alzheimer's dementia","volume":"1\u201326","author":"Matthews","year":"2020","journal-title":"SSRN Electron. J."},{"key":"10.1016\/j.ejphar.2023.176230_bib159","author":"McEachern"},{"key":"10.1016\/j.ejphar.2023.176230_bib160","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","article-title":"Intramuscular desferrioxamine in patients with Alzheimer's disease","volume":"337","author":"McLachlan","year":"1991","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejphar.2023.176230_bib161","author":"McLaurin","year":"2010"},{"key":"10.1016\/j.ejphar.2023.176230_bib162","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1039\/D0MD00196A","article-title":"Recent developments of small molecule \u03b3-secretase modulators for Alzheimer's disease","volume":"11","author":"Mekala","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejphar.2023.176230_bib163","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.1073\/pnas.95.21.12683","article-title":"Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice","volume":"95","author":"Meziane","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176230_bib164","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0006-8993(02)03731-9","article-title":"Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40)","volume":"958","author":"Miguel-Hidalgo","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2023.176230_bib165","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2023.176230_bib166","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/nm.3951","article-title":"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits","volume":"21","author":"Min","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib167","doi-asserted-by":"crossref","first-page":"911","DOI":"10.5414\/CP201816","article-title":"Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study","volume":"51","author":"Miyoshi","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib168","doi-asserted-by":"crossref","first-page":"911","DOI":"10.5414\/CP201816","article-title":"Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study","volume":"51","author":"Miyoshi","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib169","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1600-0404.1982.tb03109.x","article-title":"Epidemiology of dementia in a Finnish population","volume":"65","author":"M\u00f6ls\u00e4","year":"1982","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ejphar.2023.176230_bib170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348347","article-title":"A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment","volume":"35","author":"Morimoto","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"10.1016\/j.ejphar.2023.176230_bib171","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.3233\/JAD-190744","article-title":"Current and Emerging pharmacological targets for the treatment of alzheimer's disease","volume":"72","author":"Morsy","year":"2019","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib172","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006338","article-title":"Neurotoxicity of amyloid \u03b2-protein: synaptic and network dysfunction","volume":"2","author":"Mucke","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib173","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jama.283.8.1007","article-title":"Estrogen replacement therapy for treatment of mild to moderate alzheimer disease: a randomized controlled trial","volume":"283","author":"Mulnard","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2023.176230_bib174","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1523\/JNEUROSCI.16-13-04059.1996","article-title":"Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones","volume":"16","author":"Murphy","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib175","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","article-title":"Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study","volume":"10","author":"Murray","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib176","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nm.1912","article-title":"Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease","volume":"15","author":"Nagahara","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib177","doi-asserted-by":"crossref","first-page":"15596","DOI":"10.1523\/JNEUROSCI.5195-12.2013","article-title":"Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice","volume":"33","author":"Nagahara","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib179","series-title":"Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients - Full Text View - ClinicalTrials","year":"2008"},{"key":"10.1016\/j.ejphar.2023.176230_bib186","series-title":"Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects with Mild Cognitive Impairment or Early Alzheimer's Disease","year":"2012"},{"key":"10.1016\/j.ejphar.2023.176230_bib187","series-title":"A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease","year":"2015"},{"key":"10.1016\/j.ejphar.2023.176230_bib195","series-title":"Deferiprone to Delay Dementia (The 3D Study)","year":"2017"},{"key":"10.1016\/j.ejphar.2023.176230_bib196","series-title":"Salsalate in Patients Mild to Moderate Alzheimer's Disease","year":"2017"},{"key":"10.1016\/j.ejphar.2023.176230_bib198","series-title":"Phase 2 Study of BIIB092 in Participants with Early Alzheimer's Disease","year":"2017"},{"key":"10.1016\/j.ejphar.2023.176230_bib199","series-title":"A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects with Alzheimer's Disease [WWW Document]","year":"2017"},{"key":"10.1016\/j.ejphar.2023.176230_bib200","series-title":"Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD [WWW Document]","year":"2018"},{"key":"10.1016\/j.ejphar.2023.176230_bib201","series-title":"A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects - Full Text View - ClinicalTrials","year":"2018"},{"key":"10.1016\/j.ejphar.2023.176230_bib202","series-title":"Gene Therapy for APOE4 Homozygote of Alzheimer's Disease","year":"2023"},{"key":"10.1016\/j.ejphar.2023.176230_bib207","series-title":"A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants with Early Alzheimer's Disease (INVOKE-2)","year":"2023"},{"key":"10.1016\/j.ejphar.2023.176230_bib208","series-title":"A Follow-On Study of Donanemab (LY3002813) with Video Assessments in Participants with Alzheimer's Disease","year":"2020"},{"key":"10.1016\/j.ejphar.2023.176230_bib210","series-title":"Dominantly Inherited Alzheimer Network Trial: an Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or with a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation","year":"2022"},{"key":"10.1016\/j.ejphar.2023.176230_bib211","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3233\/JAD-170161","article-title":"Bryostatin effects on cognitive function and PKC\u03f5 in alzheimer's disease phase IIa and Expanded access trials","volume":"58","author":"Nelson","year":"2017","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib212","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809316","article-title":"The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease","volume":"10","author":"Neumann","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-014-1347-2","article-title":"The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes","volume":"129","author":"Nhan","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2023.176230_bib214","doi-asserted-by":"crossref","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-\u03b2 peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat. Med"},{"key":"10.1016\/j.ejphar.2023.176230_bib215","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176230_bib216","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00002093-199809000-00017","article-title":"Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities","volume":"12","author":"Nordberg","year":"1998","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.ejphar.2023.176230_bib217","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/156720509787313961","article-title":"Different cholinesterase inhibitor effects on CSF cholinesterases in alzheimer patients","volume":"6","author":"Nordberg","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2023.176230_bib218","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib219","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0436-1","article-title":"FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease","volume":"10","author":"Novak","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib220","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-00614-5","article-title":"Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study","volume":"12","author":"Novak","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib221","series-title":"Condensed Interim Financial Report-Supplementary Data Novartis Q3 and 9M 2019","author":"Novartis","year":"2019"},{"key":"10.1016\/j.ejphar.2023.176230_bib222","author":"Nussbaum"},{"key":"10.1016\/j.ejphar.2023.176230_bib223","doi-asserted-by":"crossref","DOI":"10.1186\/alzrt238","article-title":"Fyn kinase inhibition as a novel therapy for Alzheimer's disease","volume":"6","author":"Nygaard","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib224","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid Removal in patients with alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib225","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib226","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/epirev\/mxt008","article-title":"Postmenopausal hormone therapy is not associated with risk of all-cause dementia and alzheimer's disease","volume":"36","author":"O'Brien","year":"2014","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.ejphar.2023.176230_bib227","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and dementia with lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib228","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and dementia with lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib229","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/oxfordjournals.aje.a117244","article-title":"Estrogen deficiency and risk of Alzheimer's disease in women","volume":"140","author":"Paganini-hill","year":"1994","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ejphar.2023.176230_bib230","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3233\/JAD-140996","article-title":"N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization","volume":"43","author":"Paholikova","year":"2015","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib231","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nn.2583","article-title":"Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks","volume":"13","author":"Palop","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib232","series-title":"The Potential of Solanezumab and Gantenerumab to Prevent Alzheimer's Disease in People with Inherited Mutations that Cause its Early Onset","author":"Panza","year":"2017"},{"key":"10.1016\/j.ejphar.2023.176230_bib233","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib234","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.etap.2014.01.008","article-title":"Anti-amyloidogenic effects of ID1201, the ethanolic extract of the fruits of Melia toosendan, through activation of the phosphatidylinositol 3-kinase\/Akt pathway","volume":"37","author":"Park","year":"2014","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176230_bib235","series-title":"Compositions and Methods for Treating Alzheimer's Disease and Related Disorders and Promoting a Healthy Nervous System","author":"Pasinetti","year":"2012"},{"key":"10.1016\/j.ejphar.2023.176230_bib236","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two phase 2 multiple ascending\u2013dose studies of Vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate alzheimer's disease","volume":"51","author":"Pasquier","year":"2016","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib237","doi-asserted-by":"crossref","first-page":"P227","DOI":"10.1016\/j.jalz.2015.07.257","article-title":"O3-04-04: pharmacological intervention with the novel o-glcnacase inhibitor ASN-561 reduces pathological tau in transgenic mice","volume":"11","author":"Permanne","year":"2015","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2023.176230_bib238","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3233\/JAD-150282","article-title":"sA\u03b2PP\u03b1 is a potent endogenous inhibitor of BACE1","volume":"47","author":"Peters-Libeu","year":"2015","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib239","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcdb.2022.03.032","article-title":"Novel approaches to increase synaptic resilience as potential treatments for Alzheimer's disease","volume":"139","author":"Pham","year":"2023","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2023.176230_bib240","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/embor.2013.15","article-title":"Physiological release of endogenous tau is stimulated by neuronal activity","volume":"14","author":"Pooler","year":"2013","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejphar.2023.176230_bib241","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clinthera.2019.11.015","article-title":"A phase I study to assess the effect of speed of injection on pain, tolerability, and pharmacokinetics after high-volume subcutaneous administration of Ganteneruman in healthy volunteers","volume":"42","author":"Portron","year":"2020","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib242","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JAD-2012-111346","article-title":"Deferiprone reduces amyloid-\u03b2 and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet","volume":"30","author":"Prasanthi","year":"2012","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib243","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","article-title":"A randomized, single ascending dose study of intravenous BIIB092 in healthy participants","volume":"4","author":"Qureshi","year":"2018","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2023.176230_bib244","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","article-title":"A randomized, single ascending dose study of intravenous BIIB092 in healthy participants","volume":"4","author":"Qureshi","year":"2018","journal-title":"Alzheimer\u2019s Dement. (New York, N. Y.)"},{"key":"10.1016\/j.ejphar.2023.176230_bib245","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40263-020-00740-6","article-title":"Alzheimer's disease in down syndrome: Progress in the design and Conduct of drug prevention trials","volume":"348 34","author":"Rafii","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2023.176230_bib246","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40263-020-00740-6","article-title":"Alzheimer's disease in down syndrome: Progress in the design and Conduct of drug prevention trials","volume":"34","author":"Rafii","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2023.176230_bib247","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib248","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23020283","article-title":"Peptides as potential therapeutics for alzheimer's disease","volume":"23","author":"Ribari\u010d","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2023.176230_bib249","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib250","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S1041610209990354","article-title":"Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine","volume":"21","author":"Rodda","year":"2009","journal-title":"Int. psychogeriatrics"},{"key":"10.1016\/j.ejphar.2023.176230_bib251","doi-asserted-by":"crossref","DOI":"10.1007\/s11682-016-9541-6","article-title":"Methylene blue modulates functional connectivity in the human brain","volume":"11","author":"Rodriguez","year":"2017","journal-title":"Brain Imaging Behav"},{"key":"10.1016\/j.ejphar.2023.176230_bib252","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","article-title":"Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study","volume":"158","author":"Rogers","year":"1998","journal-title":"Donepezil Study Group. Arch. Intern. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib253","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4088\/JCP.12m08099","article-title":"Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial","volume":"74","author":"Rosenberg","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176230_bib254","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/archneur.63.10.1459","article-title":"Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein","volume":"63","author":"Rosenmann","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib255","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2174\/13892037113149990144","article-title":"CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study","volume":"10","author":"Ross","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2023.176230_bib256","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113506","article-title":"TREM2 overexpression rescues cognitive deficits in APP\/PS1 transgenic mice by reducing neuroinflammation via the JAK\/STAT\/SOCS signaling pathway","volume":"336","author":"Ruganzu","year":"2021","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib257","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2018.06.2400","article-title":"O1\u201012\u201005: phase 1 study in healthy volunteers of the O\u2010glcnacase inhibitor ASN120290 as a novel therapy for progressive supranuclear palsy and related tauopathies","volume":"14","author":"Ryan","year":"2018","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.ejphar.2023.176230_bib258","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/brain\/awy099","article-title":"Cognitive correlates of \u03b14\u03b22 nicotinic acetylcholine receptors in mild Alzheimer's dementia","volume":"141","author":"Sabri","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2023.176230_bib259","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2015.10.003","article-title":"The alpha secretase ADAM10: a metalloprotease with multiple functions in the brain","volume":"135","author":"Saftig","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2023.176230_bib260","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate alzheimer's disease A BS TR AC T","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib261","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11101-020-09677-6","article-title":"d-Pinitol: a cyclitol with versatile biological and pharmacological activities","volume":"20","author":"S\u00e1nchez-Hidalgo","year":"2021","journal-title":"Phytochem. Rev."},{"key":"10.1016\/j.ejphar.2023.176230_bib262","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trci.2016.01.001","article-title":"Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease","volume":"2","author":"Satlin","year":"2016","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2023.176230_bib263","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.176230_bib264","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-2406-5","article-title":"The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial","volume":"19","author":"Scherer","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.ejphar.2023.176230_bib265","first-page":"103","article-title":"Results from a phase II study to assess the clinical and Immunological activity of AFFITOPE\u00ae AD02 in patients with early alzheimer's disease","volume":"2","author":"Schneeberger","year":"2015","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib266","series-title":"Neuropathology of Alzheimer's Disease 21\u201331","author":"Schultz","year":"2004"},{"key":"10.1016\/j.ejphar.2023.176230_bib267","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.trci.2019.05.007","article-title":"Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease","volume":"5","author":"Schwarz","year":"2019","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2023.176230_bib268","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119129","article-title":"A review on advances of treatment modalities for Alzheimer's disease","volume":"276","author":"Se Thoe","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2023.176230_bib269","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejphar.2023.176230_bib270","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","article-title":"The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy","volume":"6","author":"Sengupta","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2023.176230_bib271","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JAD-200735","article-title":"Retinal optical Coherence Tomography Metrics are Unchanged in verubecestat alzheimer's disease clinical trial but correlate with Baseline regional brain atrophy","volume":"79","author":"Sergott","year":"2021","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib272","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological Alterations in alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring HArb PErspect MEd"},{"key":"10.1016\/j.ejphar.2023.176230_bib273","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","author":"Sevigny","year":"2016","journal-title":"Nat"},{"key":"10.1016\/j.ejphar.2023.176230_bib274","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2009.02.011","article-title":"NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model","volume":"34","author":"Shiryaev","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib275","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","article-title":"Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's health initiative memory study: a randomized controlled trial","volume":"289","author":"Shumaker","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2023.176230_bib276","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1073\/pnas.94.18.9866","article-title":"Iron accumulation in Alzheimer disease is a source of redox-generated free radicals","volume":"94","author":"Smith","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176230_bib277","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1073\/pnas.94.18.9866","article-title":"Iron accumulation in Alzheimer disease is a source of redox-generated free radicals","volume":"94","author":"Smith","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176230_bib278","doi-asserted-by":"crossref","first-page":"P261","DOI":"10.1016\/j.jalz.2016.06.469","article-title":"O2-13-04: early clinical results and preclinical validation of the O-glcnacase (OGA) inhibitor Mk-8719 as a novel therapeutic for the treatment of tauopathies","volume":"12","author":"Smith","year":"2016","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2023.176230_bib279","doi-asserted-by":"crossref","first-page":"P261","DOI":"10.1016\/j.jalz.2016.06.469","article-title":"O2-13-04: early clinical results and preclinical validation of the O-glcnacase (OGA) inhibitor Mk-8719 as a novel therapeutic for the treatment of tauopathies","volume":"12","author":"Smith","year":"2016","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2023.176230_bib280","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s12035-018-1188-4","article-title":"The gut microbiome Alterations and inflammation-driven pathogenesis of alzheimer's disease-a critical review","volume":"56","author":"Sochocka","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2023.176230_bib281","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","article-title":"An English Translation of Alzheimer's 1907 Paper \u201c\u00dcber eine eigenartige Erkrankung der Hirnrinde.\u201d","volume":"8","author":"Stelzmann","year":"1995","journal-title":"Clin. Anat."},{"key":"10.1016\/j.ejphar.2023.176230_bib282","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1212\/WNL.44.12.2300","article-title":"Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study","volume":"44","author":"Stern","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2023.176230_bib283","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101318","article-title":"Therapy for Alzheimer's disease: Missing targets and functional markers?","volume":"68","author":"Stoiljkovic","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejphar.2023.176230_bib284","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1254\/jjp.89.7","article-title":"Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor","volume":"89","author":"Sugimoto","year":"2002","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176230_bib285","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/brain\/awaa332","article-title":"BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain","volume":"143","author":"Sur","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2023.176230_bib286","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2183\/pjab.93.048","article-title":"Review the past, present, and future of disease-modifying therapies for Alzheimer's disease","volume":"93","author":"Suzuki","year":"2017","journal-title":"Proc. Jpn. Acad., Ser. B"},{"key":"10.1016\/j.ejphar.2023.176230_bib287","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10534-017-0005-2","article-title":"Effect of metal chelators on the aggregation of beta-amyloid peptides in the presence of copper and iron","volume":"30","author":"Tahmasebinia","year":"2017","journal-title":"Biometals"},{"key":"10.1016\/j.ejphar.2023.176230_bib288","series-title":"Enhancing \u03b1-secretase Processing for Alzheimer's Disease-A View on SFRP1","author":"Tang","year":"2020"},{"key":"10.1016\/j.ejphar.2023.176230_bib289","series-title":"Report about Study TRx-237-007 and the LMTX \u00ae Phase 3 Trials","year":"2016"},{"key":"10.1016\/j.ejphar.2023.176230_bib290","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of Semorinemab in individuals with prodromal to mild alzheimer disease","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib291","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.176230_bib292","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.trci.2016.08.001","article-title":"Profiling the dynamics of CSF and plasma A\u03b2 reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor","volume":"2","author":"Timmers","year":"2016","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2023.176230_bib293","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3233\/JAD-160829","article-title":"BACE1 dynamics upon inhibition with a BACE inhibitor and correlation to downstream alzheimer's disease markers in elderly healthy participants","volume":"56","author":"Timmers","year":"2017","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib294","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0415-6","article-title":"Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study","volume":"10","author":"Timmers","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib295","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40261-012-0006-4","article-title":"Effects of single doses of Avagacestat (BMS-708163) on cerebrospinal fluid A\u03b2 levels in healthy young men","volume":"3211 32","author":"Tong","year":"2012","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejphar.2023.176230_bib296","series-title":"A Contrast in Safety, Pharmacokinetics and Pharmacodynamics across Age Groups after a Single 50 Mg Oral Dose of the G-Secretase Inhibitor Avagacestat","author":"Tong","year":"2012"},{"key":"10.1016\/j.ejphar.2023.176230_bib297","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.clinthera.2012.01.022","article-title":"Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral \u03b3-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers","volume":"34","author":"Tong","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib298","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/187152709787847306","article-title":"Alternative Abeta immunotherapy approaches for Alzheimer's disease","volume":"8","author":"Town","year":"2009","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"issue":"13","key":"10.1016\/j.ejphar.2023.176230_bib299","first-page":"179","article-title":"Immunotherapeutic approaches targeting amyloid-\u03b2, \u03b1-Synuclein, and tau for the treatment of neurodegenerative disorders","volume":"131","author":"Valera","year":"2015","journal-title":"Neurother"},{"key":"10.1016\/j.ejphar.2023.176230_bib300","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic approaches targeting amyloid-\u03b2, \u03b1-Synuclein, and tau for the treatment of neurodegenerative disorders","volume":"13","author":"Valera","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2023.176230_bib301","first-page":"75","article-title":"Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early alzheimer's disease: amyloid imaging Positron Emission Tomography and safety results from a phase 2 study","volume":"3","author":"van Dyck","year":"2016","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib302","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on cerebral metabolic decline in alzheimer disease: a randomized clinical trial","volume":"76","author":"Van Dyck","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib303","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on cerebral metabolic decline in alzheimer disease: a randomized clinical trial","volume":"76","author":"Van Dyck","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib304","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib305","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib306","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer's disease: recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176230_bib307","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody Responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2023.176230_bib308","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1073\/pnas.0607919104","article-title":"Multiple-motor based transport and its regulation by Tau","volume":"104","author":"Vershinin","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176230_bib309","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid \u03b2 oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2023.176230_bib310","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib311","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","article-title":"Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression","volume":"17","author":"Wang","year":"2009","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176230_bib312","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-00678-3","article-title":"A phase II randomized trial of sodium oligomannate in Alzheimer's dementia","volume":"12","author":"Wang","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.176230_bib313","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1471-4159.2010.06615.x","article-title":"The amyloid precursor protein intracellular domain(AICD) disrupts actin dynamics and mitochondrial bioenergetics","volume":"113","author":"Ward","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2023.176230_bib314","volume":"vol. 6","author":"Weninger","year":"2020"},{"key":"10.1016\/j.ejphar.2023.176230_bib315","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of Lanabecestat for treatment of early and mild alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib316","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/alz.12164","article-title":"Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease","volume":"16","author":"Wessels","year":"2020","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.ejphar.2023.176230_bib317","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2023.176230_bib318","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib319","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium Bis(hydromethanesulphonate) (LMTM) Monotherapy for treatment of mild alzheimer's disease: Cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib320","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium Bis(hydromethanesulphonate) (LMTM) Monotherapy for treatment of mild alzheimer's disease: Cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib321","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2023.176230_bib322","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","article-title":"Tau-aggregation inhibitor therapy for Alzheimer's disease","volume":"88","author":"Wischik","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176230_bib323","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","article-title":"Tau-aggregation inhibitor therapy for Alzheimer's disease","volume":"88","author":"Wischik","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176230_bib324","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib325","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jama.279.9.688","article-title":"Estrogen therapy in postmenopausal women: effects on cognitive function and dementia","volume":"279","author":"Yaffe","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2023.176230_bib326","series-title":"Meta-Analyses of the Effect of Hormone Treatment on Cognitive Function in Postmenopausal Women","author":"Yesufu","year":"2016"},{"key":"10.1016\/j.ejphar.2023.176230_bib327","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3233\/JAD-170879","article-title":"Amyloid-\u03b2 induces AMPA receptor ubiquitination and degradation in primary neurons and human brains of alzheimer's disease","volume":"62","author":"Zhang","year":"2018","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejphar.2023.176230_bib328","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1021\/jm900504c","article-title":"Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy","volume":"52","author":"Zheng","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.176230_bib329","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jagp.2018.12.013","article-title":"Why do they just Sit? Apathy as a core symptom of alzheimer disease","volume":"27","author":"Zhu","year":"2019","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ejphar.2023.176230_bib330","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-neuro-080317-061725","article-title":"What happens with the Circuit in alzheimer's disease in mice and humans?","volume":"41","author":"Zott","year":"2018","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2023.176230_bib331","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1126\/science.aay0198","article-title":"A vicious cycle of \u03b2 amyloid-dependent neuronal hyperactivation","volume":"365","author":"Zott","year":"2019","journal-title":"Science"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923007446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923007446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:23:43Z","timestamp":1757978623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923007446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":311,"alternative-id":["S0014299923007446"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176230","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targets, trials and tribulations in Alzheimer therapeutics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"176230"}}